In a large recent study on Lynch syndrome, a gene-specific cumulative cancer risk for duodenal adenocarcinoma was reported, which was 6.5% for MLH1 and 2.0% for MSH2 carriers, but no SBA mutation was observed in patients with MSH6 or PMS2 mutations [31]. This evidence concerns the gene MSH6 and Lynch syndrome.